Table 1 Demographic and clinical characteristics
From: SERT-to-DAT ratios in early Parkinson’s disease do not correlate with the development of dyskinesias
PDNDYS(n= 27) | PDDYS(n= 23) | P value | |
|---|---|---|---|
Age of onset PD (mean ± SD) (year) | 56.8 ± 6.8 | 49.7 ± 10.9 | 0.002 |
Male sex number (percent) | 15 (56) | 16 (70) | 0.39 |
Total follow-up (mean ± SD) (months) | 155 ± 49 | 190 ± 29 | 0.004 |
Most affected side (striatal) (right/left) | 11/16 | 11/12 | 0.43 |
Disease duration (mean ± SD) (year) | 12.8 ± 4.1 | 15.8 ± 2.4 | 0.003 |
Disease duration until levodopa use (median, ICR) (year) | 3.0, 4.75 | 2.4, 2.6 | 0.57 |
Disease duration until onset dyskinesias (mean ± SD) (year) | NA | 7.8 ± 3.9 | NA |
Levodopa use until onset dyskinesias (mean ± SD) (year) | NA | 5.1 ± 3.0 | NA |
Levodopa use (mean ± SD) (year) | 9.5 ± 3.4 | 13.2 ± 2.0 | <0.001 |
UPDRS motor score at moment of imaging | 16.9 ± 6.4 | 21.4 ± 5.1 | 0.008 |
(total range, 0 to 108) (mean ± SD) | |||
Subscore A (0 to 88) | 10.8 ± 3.4 | 14.2 ± 3.4 | 0.001 |
Subscore B (0 to 20) | 6.1 ± 3.9 | 7.2 ± 2.8 | 0.25 |
Modified HY score at moment of imaging (1/1.5/2/2.5) | 7/3/8/9 | 6/1/9/7 | 0.79 |